Assembly Biosciences, a biotechnology company, reported collaboration revenue of $6.8 million for the third quarter of 2024, a significant increase from the same period in 2023 when no revenue was recorded. This revenue is part of the $21.2 million recognized under the Gilead Collaboration Agreement for the nine months ended September 30, 2024. Research and development expenses for the quarter increased by 25% to $13.5 million, driven by the advancement of the company's pipeline, including the nomination of the HDV entry inhibitor, 6250. General and administrative expenses remained consistent at $4.3 million. Interest and other income saw a 114% increase to $1.3 million due to a larger portfolio balance following the Gilead Collaboration and a financing transaction. The company's liquidity position is strong, with cash flows from investing activities at...Show More

Assembly Biosciences, a biotechnology company, reported collaboration revenue of $6.8 million for the third quarter of 2024, a significant increase from the same period in 2023 when no revenue was recorded. This revenue is part of the $21.2 million recognized under the Gilead Collaboration Agreement for the nine months ended September 30, 2024. Research and development expenses for the quarter increased by 25% to $13.5 million, driven by the advancement of the company's pipeline, including the nomination of the HDV entry inhibitor, 6250. General and administrative expenses remained consistent at $4.3 million. Interest and other income saw a 114% increase to $1.3 million due to a larger portfolio balance following the Gilead Collaboration and a financing transaction. The company's liquidity position is strong, with cash flows from investing activities at $46.9 million and financing activities providing $12.5 million. Assembly Biosciences expects its existing cash to fund operations into 2026 but acknowledges the need for additional funding for ongoing operations. The company's pipeline includes clinical-stage programs for recurrent genital herpes and chronic HBV infection, with several studies initiated in 2024 and interim results expected by the end of the year or early 2025.